New combo pill could ease opioid withdrawal for outpatients

NCT ID NCT05995535

Recruiting now Symptom relief Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding pregabalin to the standard withdrawal drug lofexidine helps people with opioid use disorder feel less sick while quitting. About 150 adults who want to start long-acting naltrexone will take either the combination or a placebo for 8 days. The goal is to see if the combo reduces withdrawal symptoms and helps more people complete detox and start recovery treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIATE WITHDRAWAL SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence opioid abuse substance withdrawal syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIATE WITHDRAWAL SYNDROME OPIOID USE

Contacts and locations

Locations

Mountain Manor Treatment Center
NOT_YET_RECRUITING

Baltimore, Maryland, 21229-3618, United States
University of Pennsylvania, Treatment Research Center
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.